Literature DB >> 6850531

A systematic approach to the evaluation and management of breast masses.

D P Winchester, S Sener, S Immerman, M Blum.   

Abstract

Between 1975 and 1980, 392 patients with a palpable mass or masses were referred for breast evaluation, including risk factor assessment, physical examination, and selective utilization of aspiration cytology and mammography. Three-hundred and thirty-one (85%) were biopsied, with a benign diagnosis in 65% of the patients and cancer in 35%. The 61 patients (15%) who were not biopsied consisted of 32 patients in whom the mass disappeared on follow-up examination, 20 with stabilization on long-term follow-up, and nine with decreased mass size. Most breast masses must be biopsied, but a few can be followed and biopsy avoided. However, a decision not to biopsy requires more precise clinical judgement and experience than a decision to proceed with biopsy. Absolute indications for breast biopsy include a clinically suspicious mass, a mammogram considered malignant or suspicious, aspiration cytologic findings reported as malignant or suspicious, and a persisting, dominant mass, even if clinically benign.

Entities:  

Mesh:

Year:  1983        PMID: 6850531     DOI: 10.1002/1097-0142(19830615)51:12+<2535::aid-cncr2820511326>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  How Many of the Biopsy Decisions Taken at Inexperienced Breast Radiology Units Were Correct?

Authors:  Özlem Demircioğlu; Meral Uluer; Erkin Arıbal
Journal:  J Breast Health       Date:  2017-01-01

2.  Breast biopsy rate and positivity in Rhode Island.

Authors:  M S Richards; J Feldman; R A Smith; B A DeBuono
Journal:  Am J Public Health       Date:  1994-08       Impact factor: 9.308

3.  Clinical, demographic, and situational factors linked to distress associated with benign breast biopsy.

Authors:  Rachel F Steffens; Heather R Wright; Molly Y Hester; Michael A Andrykowski
Journal:  J Psychosoc Oncol       Date:  2011
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.